pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-155 |
Genomic Coordinates | chr21: 25573980 - 25574044 |
Description | Homo sapiens miR-155 stem-loop |
Comment | Human mir-155 is predicted based on homology to a cloned miR from mouse (MIR:MI0000177) . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-155-3p | ||||||||||||||||||
Sequence | 43| CUCCUACAUAUUAGCAUUAACA |64 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | UBE2K | ||||||||||||||||||||
Synonyms | E2-25K, HIP2, HYPG, LIG, UBC1 | ||||||||||||||||||||
Description | ubiquitin conjugating enzyme E2 K | ||||||||||||||||||||
Transcript | NM_001111112 | ||||||||||||||||||||
Other Transcripts | NM_001111113 , NM_005339 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on UBE2K | |||||||||||||||||||||
3'UTR of UBE2K (miRNA target sites are highlighted) |
>UBE2K|NM_001111112|3'UTR 1 GGCATAGAGAGCTGCTGATATAGTCAAGCTTGCCTCTTCTTGAGGAGCACCAACATCTGTTATTTTTAGGATTCTGCATA 81 GATTTCTTTTAAACTGGCATTCTTGCCTAATGATGTTATCTAGGCACCATTGGAGACTGAAAAAAAAAAATCCCTGCTCT 161 GTAAATAAAGCTAATTAAACGTCTGTGTAAATTTAAAAAGGGGAAATACTTTAATTTTTTTTCTTAATAGTGTAAAAATT 241 CCCTGAGCTAAGCTAAAACCATGGAAGAAACATGCTACTTTAGTGTTTAGCAGTGTACCAAGACTAGCAAGAGTTTGCTT 321 CAGGATTTTGTTGAATAATTAAGATAATATTTTGAGTGTGTCAGGGCCATTCAAATTGTTGGTGTTGCATCACAGCTACC 401 TTAACTGTTTTTAACATGGATCCTCTGTGCCTGTGAATTTACTTGCATGCTTGTACTTGACTTCTTAGGATGGGTAGCTG 481 AAAAGACCACCATTTTAAGCATTTGAGAATTCTTAAATATGAAATTTATTCAGAATTGAAGATGGTGACCTATTCAGAGC 561 CTTTTTGTCCTTGTCAACAGACTGGGACAGTGTCTGATTCCCCCTTCACCCCCCCCACCCCCGCCTTGCCACACACAGCT 641 AATATTCTAATGGTAAATTTCTCTGTATCAGGTGGGGAAATGTGCTGAAGGACAGTATGTATCCCTTGCTTCATTTTTAG 721 GTCGTAGGTTTGGAATGTCTTGTCCCAGTTCTTCAAACACTCTTAAATTTTTCTTAAGTAATGTAAAAATGGAACTGCCA 801 ATTTTATTTCTCTTGCAAAAATAGTAAATACTTGATGTTACATTATTCCCAGGTTTAATGAAAGAACCCAACTTAGTTTT 881 TCAGTGAATTTGACACCTATTTTTTAGTGATGAAATTTTTCTTTGAGAACTGGCAAGGATGCAGTCAGCTGTTTGCAGTT 961 TTTAGCCTGATTTTGGGGTCTATAGAGATTGCTTTATTGGATACTTCAAGTCATTCTTGCTTGCACTTCCCCTATTGACA 1041 CATGAAAGCTGTGTTGGTGTTTTATTGTACATACTTCAGATGCACATAGGAATAGAAGTGTGTTATAAATCTAGCTTTCT 1121 TTATGATGTTTCTGATAATACGAGAATTGAAAACTTTACCTTCTCTTGTACATAGTCAGACTATTTGTATTAAATTTACA 1201 TTTCATTCTAAGTTCAAAAGTTTGAAAATTATTAGTTTTGCAAGATCACACACTAATGTAACCATTTTATGAAGGTTGAA 1281 GTGGATTTATGCAGGCAGTTCTATATATAGAAATACAATTCTTTTTAAATTTTTAGGACCAATACAAAATAACAAAAATG 1361 TAATGGAATCAGACTGAATTAAAGTAAGGCTGTATATTGAAAGTCATATTATAAAAGGTTTGCTTTCTTTAAGTGTTATT 1441 TATCTTAAATTATAATCGTTAAATGTTTGGAAGATAATTTTTGAATCATAACGTCAGCATAACTTCATTTGACTTCTCAA 1521 TAATCTTGATACTAGAAGCAATAAAAGAACCATTATTAAATATATTGTAATGTTAAAGATGTGAAGGTTCTTCCAAAAAT 1601 TTGTAAGGCTTTCCTAATTAACAGTAAACTCTTATAGCTGATATTATTACATACTAAACACAAGTTGCTGTTTTTTCCCC 1681 ATATGTTTGCTTACGCATGTCTTTATACAATCACCTCTTTTTATTGCTGTAGTTTATTTTCTAAAGATGCCAAAGGAAAC 1761 AAGATTTTTCTTTATTTATTTTAAATACCTGAAACCTCGTACTTTATATTTTGAAGTAAGGTGGGATTGTGTGAAAATGT 1841 GGATGGTTTTTCTCCAGTGTTGGTTAGAACTACTTTTTTTAAGTGGAGGGCAACTTGGTAGTATTAGTAGAATTTGGGTT 1921 TAAAAATATCAGACACATCTACCCAGTTTATTTTTTGCCTGTATTATCAGGGTATATTTAATTGTCCTGTGGTTAAACAA 2001 AGGTGAGAGAGCTCAGAGGTTTCTAAAGGTCAAGCATTTTACATATATACATACATACATGCTCTTGGAGGCAGCTATAT 2081 CCTGCTTTGATTTTTATGCACATGAGCCCTATAGGGTTATATACTCATCTAACTACACTTCAGCATCCCCAGTGCCCAAG 2161 AAATTGGAAAGTACAATATTTGGTTTGAGACATTCTTCATAAAAGATTCTTTATTATAAAAATTTACCTCATTTACATTT 2241 AATGTGATGATCTTTTTTTTCCTTTCTGGTATATTTCCCACTGTACTGTTTGGTTTTTGTTATTCTCTTGTCTGTGGGTA 2321 GATTTAGTTACCCAAACATAGAAACTAAAGCAATTGCTTTTTTCCTCTGGTCTTAAATATGTTTGGACAAAAAGACACTA 2401 AAAGGTCAGGCCTAGGGGAAAAGTACCCTGGTGGAAATTATTTTTGTAATTCTTAATATTTTTGAGTTGGCTCCGTTTGT 2481 CAGTTTTAAAAGCCTCAAAAATTATGTTAAAAAAAAAATCCAGTGAAATCCCATTTAGGGCAGGCCGATTTGTTAGAAGT 2561 CACTGATGCTCCAGTAGGCTTTTGTTATAATCAGGCCTGTTTCCTGAGTATGTGCCTCTTTTAAAAGAAGAAATAATTAG 2641 CTGTATAGTATTTCAGTACTGATGAATGAATGAATGAATGAATGGCAGTTAGTGGACCCAAATAAGTATTCAGTGGTATA 2721 TAAATATTTGAGGAACTAGGTACTGAATTAGGTGCTCTGAGTTGGCACCCCGAAATGTTTGGAATCACGACTATGATTTA 2801 CTTAAACACGTAACACATTCAAGGATATATAAATGGAGTCTAAGTATTTTGCTTTTGAAGAGAATAATCTATGAAATGGA 2881 AGACTTGATTTTTTTTTTCATTTTTTAGAAGTAATACACATTTATGATTGTTGGCACATAAAACTATGCAAAATAATTCT 2961 TTTTAAGTATCTGTAAGAAAGAATTGGCAGTTTAAACGGATTTTGCTTATTTATGCACTACAGAATGCAGCATACTGTAT 3041 TACTGTTGAGGCTGCTTAATAAGTTTACCAATGTGAAAAGCAGATCTTGGGTATAAGTGTATGCCTGATTTGAGCTTTTA 3121 AAACTGTGCAGTAGGTGTATGGTAATGTTTTACAATCCTATGTAGCAAAATAGGAAATTATGAATTTTTGTTGTTATTGT 3201 TTTAAAGATTTAAGATGGATTGGGGTAGGGAACAGCTGGAGCCAGGTATACCTTCTAGTATGTAGAGGGAAACAATGTTT 3281 AGATAGGAAAAAGGAAGCCGTCTGTTTACAGTTAACTTTATTTCATGGACTTCTACAAAATGTTGTATTAATCACTTTTT 3361 CTAGTTCAAGGAATTTCAATTCCAGGGTACAAACCATTGATTTAAAAATTACGTTTCCATTCTTTTTAGTATCAGTTTAA 3441 AGTAAATGCTTACCATCAGCCAGTTGCTGTCACTGGGAAGAAGGCAACTTGAAGTATTTACTGATAAAATAGCCTTTATT 3521 CCCAAGTGTGACTTTTCTTCAGTGTCTACATATTATGTCACACGTTCTATTTGCACTGCTGCAATATAGATCAAAGATCT 3601 TGTGGCATAGGGGTAGGGGAGTGTTAGTATCTCCCTTGTCCCATTTGTTCTGTTACTGCTTCATTGGACTGATACACCCT 3681 CATGAACTTGCAATCACCTAAATGGAAGTCTTGAATGTGTCACCTTTTGCTTGGTTATTTCAACCATGCTGCTATATATA 3761 ATCAGGTGTGGCACAGTTTGTCAGTTTGATTATAGGTGTGAGTGGATAGAAATCATTACACTGTGCTGTTAACGATCCTT 3841 GTCTGCTTGCTGTTACCTACTTTTTACAGGCATCATAATAAAAGCTAGACTATTTCTTTGGGGGGAAAGAGACTTATTTA 3921 ATGTAATTTAAAAAACTTTTCCAATAGAAAATGAAATATTATTGAAAATAATATCTATTTTTTAGCTTTCAGCAATTGAT 4001 GGTGCTTTGTTGTGGTGTCTGCTGGAAGTCTACTGCCATTATAGGGAACCTTGCTTGTTAGCTTCTCTAGATCTCTATTC 4081 TAAACAATCTGTTAGTGATGATAAATTCTGTAGGAGGGTCTATTCTGAGCCGTTAACTTCCTGTAAGGGGAAAATGGGTG 4161 GGTTACCAGAAATACCATTGAAGCAGGGTGGGCTGTGGGGTGGAAGGTTGGGGTATTTGTCTTGAGAATTAAAAACTACG 4241 AAACACTTTTGTACACAACTGATTTTTTAAAAAATAAACACATTTTTAAAGATGTTGAATTTTTCCCCCCTTATTGGGAA 4321 TTCTTAAAAATAAATGCATGCATGTTTTCCCCTGAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
miRNA:Target | ---- | |||||||||
Validation Method |
|
|||||||||
Conditions | HEK293 | |||||||||
Location of target site | 3'UTR | |||||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | |||||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
|||||||||
miRNA-target interactions (Provided by authors) |
|
|||||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 3093.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1065667. RNA binding protein: AGO1. Condition:4-thiouridine
... - Memczak S; Jens M; Elefsinioti A; Torti F; et al., 2013, Nature. |
Article |
- Memczak S; Jens M; Elefsinioti A; Torti F; et al. - Nature, 2013
Circular RNAs (circRNAs) in animals are an enigmatic class of RNA with unknown function. To explore circRNAs systematically, we sequenced and computationally analysed human, mouse and nematode RNA. We detected thousands of well-expressed, stable circRNAs, often showing tissue/developmental-stage-specific expression. Sequence analysis indicated important regulatory functions for circRNAs. We found that a human circRNA, antisense to the cerebellar degeneration-related protein 1 transcript (CDR1as), is densely bound by microRNA (miRNA) effector complexes and harbours 63 conserved binding sites for the ancient miRNA miR-7. Further analyses indicated that CDR1as functions to bind miR-7 in neuronal tissues. Human CDR1as expression in zebrafish impaired midbrain development, similar to knocking down miR-7, suggesting that CDR1as is a miRNA antagonist with a miRNA-binding capacity ten times higher than any other known transcript. Together, our data provide evidence that circRNAs form a large class of post-transcriptional regulators. Numerous circRNAs form by head-to-tail splicing of exons, suggesting previously unrecognized regulatory potential of coding sequences.
LinkOut: [PMID: 23446348]
|
CLIP-seq Support 1 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000261427.5 | 3UTR | AUUCUGUAGGAGGGUCUAUUCUGAGCCGUUAACUUCCUGUAAGGGGAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1065667 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_6 |
Location of target site | ENST00000261427.5 | 3UTR | AUUCUGUAGGAGGGUCUAUUCUGAGCCGUUAACUUCCUGUAAGGGGAAAAUGGGUGGG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
73 hsa-miR-155-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT005808 | IRAK3 | interleukin 1 receptor associated kinase 3 | 4 | 1 | ||||||||
MIRT082844 | ZNF460 | zinc finger protein 460 | 2 | 4 | ||||||||
MIRT256047 | UBE2K | ubiquitin conjugating enzyme E2 K | 2 | 4 | ||||||||
MIRT437787 | PTEN | phosphatase and tensin homolog | 2 | 1 | ||||||||
MIRT456168 | ZDHHC6 | zinc finger DHHC-type containing 6 | 2 | 2 | ||||||||
MIRT464916 | TXNIP | thioredoxin interacting protein | 2 | 4 | ||||||||
MIRT475559 | HNRNPF | heterogeneous nuclear ribonucleoprotein F | 2 | 2 | ||||||||
MIRT499608 | DNAJA1 | DnaJ heat shock protein family (Hsp40) member A1 | 2 | 8 | ||||||||
MIRT504220 | MYO6 | myosin VI | 2 | 4 | ||||||||
MIRT504256 | C1orf147 | chromosome 1 open reading frame 147 | 2 | 4 | ||||||||
MIRT507642 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT522858 | KIAA1551 | KIAA1551 | 2 | 2 | ||||||||
MIRT527505 | MYD88 | myeloid differentiation primary response 88 | 5 | 2 | ||||||||
MIRT530713 | ORMDL3 | ORMDL sphingolipid biosynthesis regulator 3 | 2 | 2 | ||||||||
MIRT532851 | ZNF699 | zinc finger protein 699 | 2 | 2 | ||||||||
MIRT535952 | MIA3 | MIA family member 3, ER export factor | 2 | 2 | ||||||||
MIRT539041 | ATXN1L | ataxin 1 like | 2 | 4 | ||||||||
MIRT556391 | LUC7L | LUC7 like | 2 | 2 | ||||||||
MIRT558617 | CNOT6L | CCR4-NOT transcription complex subunit 6 like | 2 | 2 | ||||||||
MIRT559869 | ATXN3 | ataxin 3 | 2 | 2 | ||||||||
MIRT569208 | SHC3 | SHC adaptor protein 3 | 2 | 2 | ||||||||
MIRT573122 | C18orf25 | chromosome 18 open reading frame 25 | 2 | 2 | ||||||||
MIRT575076 | Ddit4 | DNA-damage-inducible transcript 4 | 2 | 2 | ||||||||
MIRT607597 | ABCF3 | ATP binding cassette subfamily F member 3 | 2 | 6 | ||||||||
MIRT609386 | PHEX | phosphate regulating endopeptidase homolog X-linked | 2 | 2 | ||||||||
MIRT610550 | MDN1 | midasin AAA ATPase 1 | 2 | 2 | ||||||||
MIRT612390 | TCF7L2 | transcription factor 7 like 2 | 2 | 2 | ||||||||
MIRT612910 | GTDC1 | glycosyltransferase like domain containing 1 | 2 | 6 | ||||||||
MIRT613314 | ARL5C | ADP ribosylation factor like GTPase 5C | 2 | 2 | ||||||||
MIRT613356 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 2 | 4 | ||||||||
MIRT613541 | CLMP | CXADR like membrane protein | 2 | 2 | ||||||||
MIRT617029 | SYT6 | synaptotagmin 6 | 2 | 2 | ||||||||
MIRT618044 | MRVI1 | murine retrovirus integration site 1 homolog | 2 | 2 | ||||||||
MIRT619307 | KIRREL | kirre like nephrin family adhesion molecule 1 | 2 | 2 | ||||||||
MIRT623209 | MTFR1L | mitochondrial fission regulator 1 like | 2 | 2 | ||||||||
MIRT625448 | RANGAP1 | Ran GTPase activating protein 1 | 2 | 2 | ||||||||
MIRT634551 | MACC1 | MACC1, MET transcriptional regulator | 2 | 2 | ||||||||
MIRT640740 | EPB41 | erythrocyte membrane protein band 4.1 | 2 | 2 | ||||||||
MIRT640906 | RAB13 | RAB13, member RAS oncogene family | 2 | 2 | ||||||||
MIRT644025 | ZNF792 | zinc finger protein 792 | 2 | 2 | ||||||||
MIRT651489 | WT1 | Wilms tumor 1 | 2 | 2 | ||||||||
MIRT652037 | LINC00598 | long intergenic non-protein coding RNA 598 | 2 | 2 | ||||||||
MIRT669093 | CDK6 | cyclin dependent kinase 6 | 2 | 2 | ||||||||
MIRT696720 | WNT3 | Wnt family member 3 | 2 | 2 | ||||||||
MIRT698085 | TPM1 | tropomyosin 1 | 2 | 2 | ||||||||
MIRT703284 | GID4 | GID complex subunit 4 homolog | 2 | 2 | ||||||||
MIRT707183 | ARHGEF33 | Rho guanine nucleotide exchange factor 33 | 2 | 2 | ||||||||
MIRT710362 | CREB5 | cAMP responsive element binding protein 5 | 2 | 2 | ||||||||
MIRT713501 | DCAF17 | DDB1 and CUL4 associated factor 17 | 2 | 2 | ||||||||
MIRT717153 | LRRC3C | leucine rich repeat containing 3C | 2 | 2 | ||||||||
MIRT719038 | ATP1A1 | ATPase Na+/K+ transporting subunit alpha 1 | 2 | 2 | ||||||||
MIRT719489 | LSG1 | large 60S subunit nuclear export GTPase 1 | 2 | 2 | ||||||||
MIRT720284 | DPYSL3 | dihydropyrimidinase like 3 | 2 | 2 | ||||||||
MIRT732474 | NLRP3 | NLR family pyrin domain containing 3 | 2 | 0 | ||||||||
MIRT732620 | MS | multiple sclerosis | 1 | 0 | ||||||||
MIRT732968 | TGFBR2 | transforming growth factor beta receptor 2 | 3 | 0 | ||||||||
MIRT733063 | AGTR1 | angiotensin II receptor type 1 | 3 | 0 | ||||||||
MIRT733206 | ADAM10 | ADAM metallopeptidase domain 10 | 1 | 0 | ||||||||
MIRT733302 | CRP | C-reactive protein | 2 | 0 | ||||||||
MIRT734202 | PDCD4 | programmed cell death 4 | 3 | 0 | ||||||||
MIRT734467 | SIRT1 | sirtuin 1 | 2 | 0 | ||||||||
MIRT734701 | Foxo3 | forkhead box O3 | 1 | 0 | ||||||||
MIRT734889 | SP4 | Sp4 transcription factor | 2 | 0 | ||||||||
MIRT735047 | BATF | basic leucine zipper ATF-like transcription factor | 1 | 0 | ||||||||
MIRT735048 | SPI1 | Spi-1 proto-oncogene | 1 | 0 | ||||||||
MIRT735734 | PICALM | phosphatidylinositol binding clathrin assembly protein | 3 | 0 | ||||||||
MIRT735944 | TNF | tumor necrosis factor | 1 | 0 | ||||||||
MIRT736131 | MYLK | myosin light chain kinase | 2 | 0 | ||||||||
MIRT736780 | FOXP3 | forkhead box P3 | 1 | 0 | ||||||||
MIRT736781 | CEBPB | CCAAT/enhancer binding protein beta | 1 | 0 | ||||||||
MIRT736858 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 0 | ||||||||
MIRT736873 | TLR3 | toll like receptor 3 | 2 | 0 | ||||||||
MIRT736902 | CFH | complement factor H | 2 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|